The polyunsaturated fatty acid balance in kidney health and disease: A review

Marie Louise Syren, Stefano Turolo, Franca Marangoni, Gregorio P. Milani, Alberto Edefonti, Giovanni Montini, Carlo Agostoni

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Epidemiological studies show that circulating polyunsaturated fatty acids contribute to preserve renal function. In renal disease states there is generally a lack of omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) as measured in biological samples, but despite intense research for more than 30 years, it is still unclear how and to what extent their supplementation would benefit kidney disorders. Studies evaluating the n-6 series and the kidney are less frequent. The last compilation of clinical trials with n-3 LCPUFA supplements focusing on renal function and damage dates back to 2012. We here discuss n-3 and n-6 fatty acids in relation to the kidney summarizing single- and double blind randomized controlled trials performed between 2012 and 2016. Nine were sub-studies/post-hoc analyses of previous parent trials. Twelve out of the twenty trials reported on fatty acid profile or fatty acid species. Factors that may explain inconsistent results obtained after supplementation with the n-3 LCPUFA EPA and DHA in kidney disease are discussed such as baseline levels determining response, drug interaction. The need of evaluating fatty acid status before and after intervention is emphasized, to match changes in outcome measure with changes of any fatty acid potentially involved.

Original languageEnglish
Pages (from-to)1829-1839
JournalClinical Nutrition
Volume37
Issue number6 Pt A
DOIs
Publication statusPublished - 2018

Fingerprint

Kidney Diseases
Unsaturated Fatty Acids
Kidney
Fatty Acids
Health
Omega-3 Fatty Acids
Drug Interactions
Epidemiologic Studies
Randomized Controlled Trials
Outcome Assessment (Health Care)
Clinical Trials
Research

ASJC Scopus subject areas

  • Nutrition and Dietetics
  • Critical Care and Intensive Care Medicine

Cite this

The polyunsaturated fatty acid balance in kidney health and disease : A review. / Syren, Marie Louise; Turolo, Stefano; Marangoni, Franca; Milani, Gregorio P.; Edefonti, Alberto; Montini, Giovanni; Agostoni, Carlo.

In: Clinical Nutrition, Vol. 37, No. 6 Pt A, 2018, p. 1829-1839.

Research output: Contribution to journalArticle

@article{0ccbea801a844ea8bc4da824526cc7a2,
title = "The polyunsaturated fatty acid balance in kidney health and disease: A review",
abstract = "Epidemiological studies show that circulating polyunsaturated fatty acids contribute to preserve renal function. In renal disease states there is generally a lack of omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) as measured in biological samples, but despite intense research for more than 30 years, it is still unclear how and to what extent their supplementation would benefit kidney disorders. Studies evaluating the n-6 series and the kidney are less frequent. The last compilation of clinical trials with n-3 LCPUFA supplements focusing on renal function and damage dates back to 2012. We here discuss n-3 and n-6 fatty acids in relation to the kidney summarizing single- and double blind randomized controlled trials performed between 2012 and 2016. Nine were sub-studies/post-hoc analyses of previous parent trials. Twelve out of the twenty trials reported on fatty acid profile or fatty acid species. Factors that may explain inconsistent results obtained after supplementation with the n-3 LCPUFA EPA and DHA in kidney disease are discussed such as baseline levels determining response, drug interaction. The need of evaluating fatty acid status before and after intervention is emphasized, to match changes in outcome measure with changes of any fatty acid potentially involved.",
author = "Syren, {Marie Louise} and Stefano Turolo and Franca Marangoni and Milani, {Gregorio P.} and Alberto Edefonti and Giovanni Montini and Carlo Agostoni",
year = "2018",
doi = "10.1016/j.clnu.2017.11.019",
language = "English",
volume = "37",
pages = "1829--1839",
journal = "Clinical Nutrition",
issn = "0261-5614",
publisher = "Churchill Livingstone",
number = "6 Pt A",

}

TY - JOUR

T1 - The polyunsaturated fatty acid balance in kidney health and disease

T2 - A review

AU - Syren, Marie Louise

AU - Turolo, Stefano

AU - Marangoni, Franca

AU - Milani, Gregorio P.

AU - Edefonti, Alberto

AU - Montini, Giovanni

AU - Agostoni, Carlo

PY - 2018

Y1 - 2018

N2 - Epidemiological studies show that circulating polyunsaturated fatty acids contribute to preserve renal function. In renal disease states there is generally a lack of omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) as measured in biological samples, but despite intense research for more than 30 years, it is still unclear how and to what extent their supplementation would benefit kidney disorders. Studies evaluating the n-6 series and the kidney are less frequent. The last compilation of clinical trials with n-3 LCPUFA supplements focusing on renal function and damage dates back to 2012. We here discuss n-3 and n-6 fatty acids in relation to the kidney summarizing single- and double blind randomized controlled trials performed between 2012 and 2016. Nine were sub-studies/post-hoc analyses of previous parent trials. Twelve out of the twenty trials reported on fatty acid profile or fatty acid species. Factors that may explain inconsistent results obtained after supplementation with the n-3 LCPUFA EPA and DHA in kidney disease are discussed such as baseline levels determining response, drug interaction. The need of evaluating fatty acid status before and after intervention is emphasized, to match changes in outcome measure with changes of any fatty acid potentially involved.

AB - Epidemiological studies show that circulating polyunsaturated fatty acids contribute to preserve renal function. In renal disease states there is generally a lack of omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) as measured in biological samples, but despite intense research for more than 30 years, it is still unclear how and to what extent their supplementation would benefit kidney disorders. Studies evaluating the n-6 series and the kidney are less frequent. The last compilation of clinical trials with n-3 LCPUFA supplements focusing on renal function and damage dates back to 2012. We here discuss n-3 and n-6 fatty acids in relation to the kidney summarizing single- and double blind randomized controlled trials performed between 2012 and 2016. Nine were sub-studies/post-hoc analyses of previous parent trials. Twelve out of the twenty trials reported on fatty acid profile or fatty acid species. Factors that may explain inconsistent results obtained after supplementation with the n-3 LCPUFA EPA and DHA in kidney disease are discussed such as baseline levels determining response, drug interaction. The need of evaluating fatty acid status before and after intervention is emphasized, to match changes in outcome measure with changes of any fatty acid potentially involved.

UR - http://www.scopus.com/inward/record.url?scp=85039458345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039458345&partnerID=8YFLogxK

U2 - 10.1016/j.clnu.2017.11.019

DO - 10.1016/j.clnu.2017.11.019

M3 - Article

AN - SCOPUS:85039458345

VL - 37

SP - 1829

EP - 1839

JO - Clinical Nutrition

JF - Clinical Nutrition

SN - 0261-5614

IS - 6 Pt A

ER -